- Home
- KYMR vs PK Comparison
KYMR vs PK Comparison
Compare KYMR & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- PK
- Stock Information
- Founded
- KYMR 2015
- PK 1946
- Country
- KYMR United States
- PK United States
- Employees
- KYMR N/A
- PK N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- PK Real Estate Investment Trusts
- Sector
- KYMR Health Care
- PK Real Estate
- Exchange
- KYMR Nasdaq
- PK Nasdaq
- Market Cap
- KYMR 3.0B
- PK 3.0B
- IPO Year
- KYMR 2020
- PK N/A
- Fundamental
- Price
- KYMR $41.96
- PK $14.57
- Analyst Decision
- KYMR Buy
- PK Buy
- Analyst Count
- KYMR 13
- PK 13
- Target Price
- KYMR $51.15
- PK $18.50
- AVG Volume (30 Days)
- KYMR 415.6K
- PK 3.6M
- Earning Date
- KYMR 10-31-2024
- PK 10-29-2024
- Dividend Yield
- KYMR N/A
- PK 6.90%
- EPS Growth
- KYMR N/A
- PK N/A
- EPS
- KYMR N/A
- PK 1.57
- Revenue
- KYMR $87,563,000.00
- PK $2,662,000,000.00
- Revenue This Year
- KYMR N/A
- PK N/A
- Revenue Next Year
- KYMR $21.47
- PK $4.18
- P/E Ratio
- KYMR N/A
- PK $9.24
- Revenue Growth
- KYMR 86.92
- PK N/A
- 52 Week Low
- KYMR $17.89
- PK $13.24
- 52 Week High
- KYMR $53.27
- PK $18.05
- Technical
- Relative Strength Index (RSI)
- KYMR 34.56
- PK 56.94
- Support Level
- KYMR $45.16
- PK $14.68
- Resistance Level
- KYMR $53.23
- PK $15.42
- Average True Range (ATR)
- KYMR 2.58
- PK 0.47
- MACD
- KYMR -0.54
- PK 0.08
- Stochastic Oscillator
- KYMR 1.66
- PK 63.50
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 23,428 rooms across 39 hotels in the United States. Park also has interests through joint ventures in another 2,665 rooms in four U.S. hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality U.S. hotels to focus on high-quality assets in domestic gateway markets.